Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Orion Office REIT Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Orion Office REIT Inc trades at $2.7 (market cap $156.28M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 255.2× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 2.91% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | ONL | |
|---|---|---|
Market Cap | $39.89B | $156.28M |
Sector | Health | Real Estate |
52-Week High | $491.22 | $3.04 |
52-Week Low | $278.09 | $1.93 |
Enterprise Value | $38.15B | $639.94M |
Dividend Yield | — | 2.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
ONL trades at $2.75, down 1.08% on the day, with a neutral technical signal and bearish moving averages. The company reported a net loss of $139.31 million in 2025, with revenue declining to $147.65 million. Despite negative profitability, the stock trades at a low price-to-book ratio of 0.26 and recently announced a $0.02 dividend. Strategic reviews and portfolio repositioning are ongoing, as noted in recent earnings calls (Business Wire, 2026-05-07).
Outlook remains challenged by persistent losses and high debt, but strategic asset sales and refinancing improvements offer potential stabilization. Risks include further revenue declines and office sector headwinds, while analyst sentiment is evenly split between buy and hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
